| ◆英語タイトル：Pediatric Neuroblastoma Treatment Market By Therapy Type (Immunotherapy, Chemotherapy & Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores) & By Region - Global Market Insights 2023 to 2033
|
 | ◆商品コード：FACT23MA122
◆発行会社（リサーチ会社）：FactMR
◆発行日：2023年3月21日
◆ページ数：約170
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：医療
|
◆販売価格オプション
（消費税別）
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
Fact.MR社の本調査資料は、世界の小児神経芽腫治療市場について2023年から2033年までの現状・動向について調査した最新レポートです。当書は、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場展望、治療種類別（免疫療法、化学療法、その他）分析、流通チャネル別（病院薬局、小売薬局、ドラッグストア）分析、地域別（北米、ヨーロッパ、その他地域）分析などの分析結果をまとめたものです。なお、当書には、United Therapeutics Corporation、APEIRON Biologics AG、Baxterなどの企業情報が含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・市場展望
・世界の小児神経芽腫治療市場規模：治療種類別
- 免疫療法の市場規模
- 化学療法の市場規模
- その他治療種類の市場規模
・世界の小児神経芽腫治療市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- ドラッグストアチャネルの市場規模
・世界の小児神経芽腫治療市場規模：地域別
- 北米の小児神経芽腫治療市場規模
- ヨーロッパの小児神経芽腫治療市場規模
- その他地域の小児神経芽腫治療市場規模
・企業情報
本レポートには、各企業の製品ポートフォリオや主要戦略、包括的なSWOT分析などの要素を含む企業情報が含まれています。企業のプレゼンスは、全著名プレーヤーについてマッピングされ、マトリックスを通して提示されます。なお、購読者に実用的な洞察を提供し、熟考して市場の状況を示し、小児神経芽腫治療における競争レベルを推測するのに役立ちます。 |
Pediatric Neuroblastoma Treatment Market – Scope of Report
A recent study by Fact.MR on the pediatric neuroblastoma treatment market offers a 10-year forecast for 2023 to 2033. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering pediatric neuroblastoma treatment.
The study also provides the dynamics responsible for influencing the future status of the pediatric neuroblastoma treatment market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.
A list of prominent companies operating in the pediatric neuroblastoma treatment market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.
Report Summary
The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of pediatric neuroblastoma treatment across the globe.
A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of pediatric neuroblastoma treatment during the forecast period. Price point comparison by region with global average price is also considered in the study.
Analysis on Market Size Evaluation
The market has been analyzed for each segment in terms of value (US$ Mn).
Estimates at global and regional levels for pediatric neuroblastoma treatment are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.
Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global pediatric neuroblastoma treatment market.
Inspected Assessment on Regional Segments
Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the pediatric neuroblastoma treatment market during the forecast period.
Country-specific valuation on demand for pediatric neuroblastoma treatment has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value & volume for emerging countries has also been included in the report.
In-depth Analysis on Competition
The report sheds light on leading manufacturers of pediatric neuroblastoma treatment, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering pediatric neuroblastoma treatment has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the pediatric neuroblastoma treatment domain.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Market Analysis and Forecast, 2023–2033
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Epidemiology Pediatric Neuroblastoma
5.2. Pipeline Analysis
5.3. Key Unmet Needs in the Market
5.4. Global Market: Rate of Metastasis in Neuroblastoma
5.5. Global Market: Neuroblastoma Relapse/Refractory cases
5.6. Rate of Utilization of MIBG-131
6. Global Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapy Type, 2023–2033
6.3.1. Immunotherapy
6.3.2. Chemotherapy
6.3.3. Others
6.4. Market Attractiveness, by Therapy Type
7. Global Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2023–2033
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies & Drug Stores
7.4. Market Attractiveness, by Distribution Channel
8. Global Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Rest of the World
8.3. Market Attractiveness, by Region
9. North America Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Therapy Type, 2023–2033
9.2.1. Immunotherapy
9.2.2. Chemotherapy
9.2.3. Others
9.3. Market Value Forecast, by Distribution Channel, 2023–2033
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies & Drug Stores
9.4. Market Value Forecast, by Country, 2023–2033
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Therapy Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Therapy Type, 2023–2033
10.2.1. Immunotherapy
10.2.2. Chemotherapy
10.2.3. Others
10.3. Market Value Forecast, by Distribution Channel, 2023–2033
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies & Drug Stores
10.4. Market Value Forecast, by Country/Sub-region, 2023–2033
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Therapy Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Rest of the World Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapy Type, 2023–2033
11.2.1. Immunotherapy
11.2.2. Chemotherapy
11.2.3. Others
11.3. Market Value Forecast, by Distribution Channel, 2023–2033
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies & Drug Stores
11.4. Market Attractiveness Analysis
11.4.1. By Therapy Type
11.4.2. By Distribution Channel
12. Company Profiles
12.1. United Therapeutics Corporation
12.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.2. Product Portfolio
12.1.3. SWOT Analysis
12.1.4. Financial Overview
12.1.5. Strategic Overview
12.2. APEIRON Biologics AG
12.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.2. Product Portfolio
12.2.3. SWOT Analysis
12.2.4. Financial Overview
12.2.5. Strategic Overview
12.3. Baxter
12.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.2. Product Portfolio
12.3.3. SWOT Analysis
12.3.4. Financial Overview
12.3.5. Strategic Overview
12.4. Cellectar Biosciences, Inc.
12.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.4.2. Product Portfolio
12.4.3. SWOT Analysis
12.4.4. Financial Overview
12.4.5. Strategic Overview
12.5. Pfizer, Inc.
12.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.5.2. Product Portfolio
12.5.3. SWOT Analysis
12.5.4. Financial Overview
12.5.5. Strategic Overview
12.6. MacroGenics, Inc.
12.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.6.2. Product Portfolio
12.6.3. SWOT Analysis
12.6.4. Financial Overview
12.6.5. Strategic Overview
12.7. Bayer AG
12.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.7.2. Product Portfolio
12.7.3. SWOT Analysis
12.7.4. Financial Overview
12.7.5. Strategic Overview
❖ 免責事項 ❖http://www.globalresearch.jp/disclaimer
